Pirenperone

Pirenperone is an antipsychotic drug that was developed in the 1970s. It is classified as an atypical antipsychotic due to its unique pharmacological properties. Pirenperone has been studied for its potential use in the treatment of schizophrenia, but it has not been widely adopted in clinical practice.

Pharmacology

Pirenperone acts as an antagonist at the D2 dopamine receptor and the 5-HT2A serotonin receptor, which are both implicated in the pathophysiology of schizophrenia. It also has affinity for the H1 histamine receptor and the alpha-1 adrenergic receptor, which may contribute to its side effect profile.

Clinical Use

While pirenperone has been studied in clinical trials for the treatment of schizophrenia, it has not been widely adopted in clinical practice. The reasons for this are not entirely clear, but may relate to its side effect profile or lack of clear superiority over other available antipsychotic drugs.

Side Effects

Like many antipsychotic drugs, pirenperone can cause a range of side effects. These may include sedation, orthostatic hypotension, and anticholinergic effects such as dry mouth and constipation. It may also cause extrapyramidal symptoms such as tremor and rigidity, although these are generally less common with atypical antipsychotics like pirenperone than with older, typical antipsychotics.

See Also

• Atypical antipsychotic
• Dopamine receptor D2
• Serotonin receptor 5-HT2A
• Histamine receptor H1
• Alpha-1 adrenergic receptor

Pirenperone Resources
Latest articles Most recent articles Ongoing trials	Wikipedia